Is KALV or BNTC more profitable?

Benitec Biopharma's return on equity of -34.82% beat KalVista Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets KalVista Pharmaceuticals N/A -341.44% -111.94% Benitec Biopharma N/A -34.82% -34.11%

Does the media refer more to KALV or BNTC?

In the previous week, KalVista Pharmaceuticals had 1 more articles in the media than Benitec Biopharma. MarketBeat recorded 2 mentions for KalVista Pharmaceuticals and 1 mentions for Benitec Biopharma. KalVista Pharmaceuticals' average media sentiment score of 0.58 beat Benitec Biopharma's score of -0.54 indicating that KalVista Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment KalVista Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Benitec Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

Is DMRA or BNTC more profitable?

Benitec Biopharma's return on equity of -34.82% beat Damora Therapeutics, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Damora Therapeutics, Inc. Common Stock N/A -428.30% -114.62% Benitec Biopharma N/A -34.82% -34.11%

Is BNTC or AVBP more profitable?

Benitec Biopharma's return on equity of -34.82% beat ArriVent BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets Benitec Biopharma N/A -34.82% -34.11% ArriVent BioPharma N/A -48.98% -45.44%

Does the media prefer BNTC or AVBP?

In the previous week, Benitec Biopharma and Benitec Biopharma both had 1 articles in the media. ArriVent BioPharma's average media sentiment score of 1.32 beat Benitec Biopharma's score of -0.54 indicating that ArriVent BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Benitec Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative ArriVent BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BNTC or PGEN?

In the previous week, Precigen had 2 more articles in the media than Benitec Biopharma. MarketBeat recorded 3 mentions for Precigen and 1 mentions for Benitec Biopharma. Benitec Biopharma's average media sentiment score of -0.54 beat Precigen's score of -0.57 indicating that Benitec Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Benitec Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Precigen 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

Is BNTC or INBX more profitable?

Benitec Biopharma's return on equity of -34.82% beat Inhibrx Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Benitec Biopharma N/A -34.82% -34.11% Inhibrx Biosciences N/A -563.90% -72.32%

Benitec Biopharma (BNTC) Competitors

$10.50 -0.05 (-0.47%)

Closing price 04:00 PM Eastern

Extended Trading

$10.51 +0.01 (+0.10%)

As of 04:47 PM Eastern

Compare

BNTC vs. KALV, DMRA, AVBP, PGEN, and INBX

Should you buy Benitec Biopharma stock or one of its competitors? MarketBeat compares Benitec Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Benitec Biopharma include KalVista Pharmaceuticals (KALV), Damora Therapeutics, Inc. Common Stock (DMRA), ArriVent BioPharma (AVBP), Precigen (PGEN), and Inhibrx Biosciences (INBX). These companies are all part of the "pharmaceutical products" industry.

How does Benitec Biopharma compare to KalVista Pharmaceuticals?

KalVista Pharmaceuticals (NASDAQ:KALV) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment.

KalVista Pharmaceuticals currently has a consensus price target of $30.60, indicating a potential upside of 13.38%. Benitec Biopharma has a consensus price target of $27.00, indicating a potential upside of 157.14%. Given Benitec Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Benitec Biopharma is more favorable than KalVista Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KalVista Pharmaceuticals	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.22
Benitec Biopharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

KalVista Pharmaceuticals has a beta of -0.12, indicating that its stock price is 112% less volatile than the broader market. Comparatively, Benitec Biopharma has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market.

Benitec Biopharma has lower revenue, but higher earnings than KalVista Pharmaceuticals. Benitec Biopharma is trading at a lower price-to-earnings ratio than KalVista Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KalVista Pharmaceuticals	$49.08M	29.28	-$109.52M	-$3.46	N/A
Benitec Biopharma	$80K	4,508.44	-$37.92M	-$1.14	N/A

Benitec Biopharma's return on equity of -34.82% beat KalVista Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KalVista Pharmaceuticals	N/A	-341.44%	-111.94%
Benitec Biopharma	N/A	-34.82%	-34.11%

In the previous week, KalVista Pharmaceuticals had 1 more articles in the media than Benitec Biopharma. MarketBeat recorded 2 mentions for KalVista Pharmaceuticals and 1 mentions for Benitec Biopharma. KalVista Pharmaceuticals' average media sentiment score of 0.58 beat Benitec Biopharma's score of -0.54 indicating that KalVista Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
KalVista Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Benitec Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

52.2% of Benitec Biopharma shares are owned by institutional investors. 4.3% of KalVista Pharmaceuticals shares are owned by insiders. Comparatively, 4.8% of Benitec Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Benitec Biopharma beats KalVista Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

How does Benitec Biopharma compare to Damora Therapeutics, Inc. Common Stock?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.

Benitec Biopharma's return on equity of -34.82% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Damora Therapeutics, Inc. Common Stock	N/A	-428.30%	-114.62%
Benitec Biopharma	N/A	-34.82%	-34.11%

Damora Therapeutics, Inc. Common Stock currently has a consensus price target of $42.00, indicating a potential upside of 100.86%. Benitec Biopharma has a consensus price target of $27.00, indicating a potential upside of 157.14%. Given Benitec Biopharma's higher possible upside, analysts plainly believe Benitec Biopharma is more favorable than Damora Therapeutics, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90
Benitec Biopharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Damora Therapeutics, Inc. Common Stock has a beta of 1.46, suggesting that its share price is 46% more volatile than the broader market. Comparatively, Benitec Biopharma has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market.

In the previous week, Damora Therapeutics, Inc. Common Stock and Damora Therapeutics, Inc. Common Stock both had 1 articles in the media. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 0.50 beat Benitec Biopharma's score of -0.54 indicating that Damora Therapeutics, Inc. Common Stock is being referred to more favorably in the media.

Company	Overall Sentiment
Damora Therapeutics, Inc. Common Stock	Positive
Benitec Biopharma	Negative

14.2% of Damora Therapeutics, Inc. Common Stock shares are owned by institutional investors. Comparatively, 52.2% of Benitec Biopharma shares are owned by institutional investors. 0.4% of Damora Therapeutics, Inc. Common Stock shares are owned by company insiders. Comparatively, 4.8% of Benitec Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Benitec Biopharma has higher revenue and earnings than Damora Therapeutics, Inc. Common Stock. Benitec Biopharma is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$5.58	N/A
Benitec Biopharma	$80K	4,508.44	-$37.92M	-$1.14	N/A

Summary

Benitec Biopharma beats Damora Therapeutics, Inc. Common Stock on 8 of the 12 factors compared between the two stocks.

How does Benitec Biopharma compare to ArriVent BioPharma?

Benitec Biopharma (NASDAQ:BNTC) and ArriVent BioPharma (NASDAQ:AVBP) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment.

In the previous week, Benitec Biopharma and Benitec Biopharma both had 1 articles in the media. ArriVent BioPharma's average media sentiment score of 1.32 beat Benitec Biopharma's score of -0.54 indicating that ArriVent BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Benitec Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
ArriVent BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Benitec Biopharma has higher revenue and earnings than ArriVent BioPharma. Benitec Biopharma is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Benitec Biopharma	$80K	4,508.44	-$37.92M	-$1.14	N/A
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A

Benitec Biopharma has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market.

Benitec Biopharma currently has a consensus target price of $27.00, indicating a potential upside of 157.14%. ArriVent BioPharma has a consensus target price of $43.38, indicating a potential upside of 42.21%. Given Benitec Biopharma's higher possible upside, research analysts clearly believe Benitec Biopharma is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Benitec Biopharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Benitec Biopharma's return on equity of -34.82% beat ArriVent BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Benitec Biopharma	N/A	-34.82%	-34.11%
ArriVent BioPharma	N/A	-48.98%	-45.44%

52.2% of Benitec Biopharma shares are owned by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are owned by institutional investors. 4.8% of Benitec Biopharma shares are owned by company insiders. Comparatively, 8.6% of ArriVent BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Benitec Biopharma beats ArriVent BioPharma on 7 of the 13 factors compared between the two stocks.

How does Benitec Biopharma compare to Precigen?

Benitec Biopharma (NASDAQ:BNTC) and Precigen (NASDAQ:PGEN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

Benitec Biopharma has a net margin of 0.00% compared to Precigen's net margin of -646.99%. Precigen's return on equity of 717.50% beat Benitec Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Benitec Biopharma	N/A	-34.82%	-34.11%
Precigen	-646.99%	717.50%	58.48%

In the previous week, Precigen had 2 more articles in the media than Benitec Biopharma. MarketBeat recorded 3 mentions for Precigen and 1 mentions for Benitec Biopharma. Benitec Biopharma's average media sentiment score of -0.54 beat Precigen's score of -0.57 indicating that Benitec Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Benitec Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
Precigen	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Benitec Biopharma currently has a consensus price target of $27.00, suggesting a potential upside of 157.14%. Precigen has a consensus price target of $12.50, suggesting a potential upside of 250.14%. Given Precigen's higher possible upside, analysts clearly believe Precigen is more favorable than Benitec Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Benitec Biopharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Precigen	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Benitec Biopharma has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market. Comparatively, Precigen has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market.

Benitec Biopharma has higher earnings, but lower revenue than Precigen. Benitec Biopharma is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Benitec Biopharma	$80K	4,508.44	-$37.92M	-$1.14	N/A
Precigen	$9.68M	131.48	-$250.64M	-$1.18	N/A

52.2% of Benitec Biopharma shares are held by institutional investors. Comparatively, 33.5% of Precigen shares are held by institutional investors. 4.8% of Benitec Biopharma shares are held by insiders. Comparatively, 47.1% of Precigen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Benitec Biopharma and Precigen tied by winning 8 of the 16 factors compared between the two stocks.

How does Benitec Biopharma compare to Inhibrx Biosciences?

Benitec Biopharma (NASDAQ:BNTC) and Inhibrx Biosciences (NASDAQ:INBX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

Benitec Biopharma has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market. Comparatively, Inhibrx Biosciences has a beta of 3.33, suggesting that its share price is 233% more volatile than the broader market.

Benitec Biopharma has higher earnings, but lower revenue than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Benitec Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Benitec Biopharma	$80K	4,508.44	-$37.92M	-$1.14	N/A
Inhibrx Biosciences	$1.30M	1,005.80	-$140.05M	-$8.39	N/A

Benitec Biopharma's return on equity of -34.82% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Benitec Biopharma	N/A	-34.82%	-34.11%
Inhibrx Biosciences	N/A	-563.90%	-72.32%

52.2% of Benitec Biopharma shares are held by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are held by institutional investors. 4.8% of Benitec Biopharma shares are held by insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Benitec Biopharma had 1 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 1 mentions for Benitec Biopharma and 0 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 0.00 beat Benitec Biopharma's score of -0.54 indicating that Inhibrx Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Benitec Biopharma	Negative
Inhibrx Biosciences	Neutral

Benitec Biopharma presently has a consensus price target of $27.00, suggesting a potential upside of 157.14%. Inhibrx Biosciences has a consensus price target of $150.00, suggesting a potential upside of 68.29%. Given Benitec Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Benitec Biopharma is more favorable than Inhibrx Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Benitec Biopharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33

Summary

Benitec Biopharma beats Inhibrx Biosciences on 9 of the 15 factors compared between the two stocks.

Get Benitec Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BNTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BNTC vs. The Competition

Export

Metric	Benitec Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$362.44M	$3.30B	$6.43B	$12.05B
Dividend Yield	N/A	2.31%	2.67%	5.56%
P/E Ratio	-9.21	18.93	23.75	23.75
Price / Sales	4,508.44	173.93	479.99	83.74
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	2.83	8.04	10.28	6.78
Net Income	-$37.92M	$23.89M	$3.57B	$337.51M
7 Day Performance	-2.96%	-5.97%	-1.43%	-2.72%
1 Month Performance	-14.50%	2.78%	3.27%	1.87%
1 Year Performance	-34.38%	36.26%	23.37%	26.61%

Benitec Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BNTC Benitec Biopharma	1.4199 of 5 stars	$10.50 -0.5%	$27.00 +157.1%	-34.1%	$362.44M	$80K	N/A	20	News Coverage Gap Down
KALV KalVista Pharmaceuticals	2.6454 of 5 stars	$26.94 flat	$30.60 +13.6%	+87.7%	$1.43B	$1.43M	N/A	100
DMRA Damora Therapeutics, Inc. Common Stock	2.7031 of 5 stars	$22.95 -7.6%	$42.00 +83.0%	+538.6%	$1.41B	N/A	N/A	40	Analyst Forecast Gap Up
AVBP ArriVent BioPharma	2.5461 of 5 stars	$29.92 -2.5%	$43.38 +45.0%	+29.0%	$1.39B	N/A	N/A	40
PGEN Precigen	2.5828 of 5 stars	$3.86 -6.3%	$12.50 +223.8%	+138.7%	$1.38B	$9.68M	N/A	190	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BNTC) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Benitec Biopharma (BNTC) Competitors

BNTC vs. KALV, DMRA, AVBP, PGEN, and INBX

How does Benitec Biopharma compare to KalVista Pharmaceuticals?

Summary

How does Benitec Biopharma compare to Damora Therapeutics, Inc. Common Stock?

Summary

How does Benitec Biopharma compare to ArriVent BioPharma?

Summary

How does Benitec Biopharma compare to Precigen?

Summary

How does Benitec Biopharma compare to Inhibrx Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNTC vs. The Competition

Benitec Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Benitec Biopharma (BNTC) Competitors

BNTC vs. KALV, DMRA, AVBP, PGEN, and INBX

How does Benitec Biopharma compare to KalVista Pharmaceuticals?

Do analysts recommend KALV or BNTC?

Which has more volatility and risk, KALV or BNTC?

Which has preferable valuation & earnings, KALV or BNTC?

Is KALV or BNTC more profitable?

Does the media refer more to KALV or BNTC?

Do insiders and institutionals have more ownership in KALV or BNTC?

Summary

How does Benitec Biopharma compare to Damora Therapeutics, Inc. Common Stock?

Is DMRA or BNTC more profitable?

Do analysts rate DMRA or BNTC?

Which has more volatility and risk, DMRA or BNTC?

Does the media refer more to DMRA or BNTC?

Do insiders & institutionals have more ownership in DMRA or BNTC?

Which has preferable earnings & valuation, DMRA or BNTC?

Summary

How does Benitec Biopharma compare to ArriVent BioPharma?

Does the media prefer BNTC or AVBP?

Which has preferable earnings & valuation, BNTC or AVBP?

Which has more risk & volatility, BNTC or AVBP?

Do analysts rate BNTC or AVBP?

Is BNTC or AVBP more profitable?

Do insiders and institutionals believe in BNTC or AVBP?

Summary

How does Benitec Biopharma compare to Precigen?

Is BNTC or PGEN more profitable?

Does the media refer more to BNTC or PGEN?

Do analysts rate BNTC or PGEN?

Which has more risk and volatility, BNTC or PGEN?

Which has higher earnings & valuation, BNTC or PGEN?

Do insiders & institutionals believe in BNTC or PGEN?

Summary

How does Benitec Biopharma compare to Inhibrx Biosciences?

Which has more risk and volatility, BNTC or INBX?

Which has better earnings and valuation, BNTC or INBX?

Is BNTC or INBX more profitable?

Do insiders and institutionals hold more shares of BNTC or INBX?

Does the media prefer BNTC or INBX?

Do analysts prefer BNTC or INBX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNTC vs. The Competition

Benitec Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools